150 related articles for article (PubMed ID: 37706370)
1. Association of
Asadov C; Karimova N; Hasanova A; Bayramov B; Shirinova A; Alimirzoyeva Z
Indian J Med Res; 2023 Aug; 158(2):151-160. PubMed ID: 37706370
[TBL] [Abstract][Full Text] [Related]
2. Impact of
Maddin N; Husin A; Gan SH; Aziz BA; Ankathil R
Oncol Ther; 2016; 4(2):303-314. PubMed ID: 28261657
[TBL] [Abstract][Full Text] [Related]
3. Influence of MDR1 and CYP3A5 genetic polymorphisms on trough levels and therapeutic response of imatinib in newly diagnosed patients with chronic myeloid leukemia.
Harivenkatesh N; Kumar L; Bakhshi S; Sharma A; Kabra M; Velpandian T; Gogia A; Shastri SS; Biswas NR; Gupta YK
Pharmacol Res; 2017 Jun; 120():138-145. PubMed ID: 28330783
[TBL] [Abstract][Full Text] [Related]
4. Impact of Fas/Fasl Gene Polymorphisms on Susceptibility Risk and Imatinib Mesylate Treatment Response in Chronic Myeloid Leukaemia Patients.
Annuar AA; Ankathil R; Mohd Yunus N; Husin A; Ab Rajab NS; Abdul Aziz AA; Ibrahim MI; Sulong S
Asian Pac J Cancer Prev; 2021 Feb; 22(2):565-571. PubMed ID: 33639675
[TBL] [Abstract][Full Text] [Related]
5. Do SLCO1B3 (T334G) and CYP3A5*3 polymorphisms affect response in Egyptian chronic myeloid leukemia patients receiving imatinib therapy?
Bedewy AM; El-Maghraby SM
Hematology; 2013 Jul; 18(4):211-6. PubMed ID: 23394475
[TBL] [Abstract][Full Text] [Related]
6. Influence of CYP3A5*3 and ABCB1 C3435T on clinical outcomes and trough plasma concentrations of imatinib in Nigerians with chronic myeloid leukaemia.
Adeagbo BA; Bolaji OO; Olugbade TA; Durosinmi MA; Bolarinwa RA; Masimirembwa C
J Clin Pharm Ther; 2016 Oct; 41(5):546-51. PubMed ID: 27426203
[TBL] [Abstract][Full Text] [Related]
7. Impact of SLC22A1 and CYP3A5 genotypes on imatinib response in chronic myeloid leukemia: A systematic review and meta-analysis.
Cargnin S; Ravegnini G; Soverini S; Angelini S; Terrazzino S
Pharmacol Res; 2018 May; 131():244-254. PubMed ID: 29427770
[TBL] [Abstract][Full Text] [Related]
8. Functional polymorphism of CYP2B6 G15631T is associated with hematologic and cytogenetic response in chronic myeloid leukemia patients treated with imatinib.
Kassogue Y; Quachouh M; Dehbi H; Quessar A; Benchekroun S; Nadifi S
Med Oncol; 2014 Jan; 31(1):782. PubMed ID: 24293093
[TBL] [Abstract][Full Text] [Related]
9. Association of GSTM1, GSTT1 and GSTP1 Ile105Val polymorphisms with clinical response to imatinib mesylate treatment among Malaysian chronic myeloid leukaemia patients.
Makhtar SM; Husin A; Baba AA; Ankathil R
J Genet; 2017 Sep; 96(4):633-639. PubMed ID: 28947711
[TBL] [Abstract][Full Text] [Related]
10. Do polymorphisms in MDR1 and CYP3A5 genes influence the risk of cytogenetic relapse in patients with chronic myeloid leukemia on imatinib therapy?
Harivenkatesh N; Kumar L; Bakhshi S; Sharma A; Kabra M; Velpandian T; Gogia A; Shastri SS; Gupta YK
Leuk Lymphoma; 2017 Sep; 58(9):1-9. PubMed ID: 28367681
[TBL] [Abstract][Full Text] [Related]
11. Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia.
Kim DH; Sriharsha L; Xu W; Kamel-Reid S; Liu X; Siminovitch K; Messner HA; Lipton JH
Clin Cancer Res; 2009 Jul; 15(14):4750-8. PubMed ID: 19584153
[TBL] [Abstract][Full Text] [Related]
12. Association of genotypes and haplotypes of multi-drug transporter genes ABCB1 and ABCG2 with clinical response to imatinib mesylate in chronic myeloid leukemia patients.
Au A; Aziz Baba A; Goh AS; Wahid Fadilah SA; Teh A; Rosline H; Ankathil R
Biomed Pharmacother; 2014 Apr; 68(3):343-9. PubMed ID: 24581936
[TBL] [Abstract][Full Text] [Related]
13. hOCT1 gene expression predict for optimal response to Imatinib in Tunisian patients with chronic myeloid leukemia.
Ben Hassine I; Gharbi H; Soltani I; Teber M; Farrah A; Ben Hadj Othman H; Amouri H; Bellaaj H; Lakhal RB; Romdhane NB; Abbes S; Menif S
Cancer Chemother Pharmacol; 2017 Apr; 79(4):737-745. PubMed ID: 28286932
[TBL] [Abstract][Full Text] [Related]
14. Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy.
Angelini S; Soverini S; Ravegnini G; Barnett M; Turrini E; Thornquist M; Pane F; Hughes TP; White DL; Radich J; Kim DW; Saglio G; Cilloni D; Iacobucci I; Perini G; Woodman R; Cantelli-Forti G; Baccarani M; Hrelia P; Martinelli G
Haematologica; 2013 Feb; 98(2):193-200. PubMed ID: 22875622
[TBL] [Abstract][Full Text] [Related]
15. Genetic variations in influx transporter gene
Makhtar SM; Husin A; Baba AA; Ankathil R
J Genet; 2018 Sep; 97(4):835-842. PubMed ID: 30262695
[TBL] [Abstract][Full Text] [Related]
16. Influence of genetic polymorphisms on imatinib concentration and therapeutic response in patients with chronic-phase chronic myeloid leukemia.
Cheng F; Cui Z; Li Q; Chen S; Li W; Zhang Y
Int Immunopharmacol; 2024 May; 133():112090. PubMed ID: 38640718
[TBL] [Abstract][Full Text] [Related]
17. Genetic variations of hOCT1 gene and CYP3A4/A5 genes and their association with imatinib response in Chronic Myeloid Leukemia.
Vaidya S; Ghosh K; Shanmukhaiah C; Vundinti BR
Eur J Pharmacol; 2015 Oct; 765():124-30. PubMed ID: 26300393
[TBL] [Abstract][Full Text] [Related]
18. Influence of enzyme and transporter polymorphisms on trough imatinib concentration and clinical response in chronic myeloid leukemia patients.
Seong SJ; Lim M; Sohn SK; Moon JH; Oh SJ; Kim BS; Ryoo HM; Chung JS; Joo YD; Bang SM; Jung CW; Kim DH; Park SY; Yoon SS; Kim I; Lee HG; Won JH; Min YH; Cheong JW; Park JS; Eom KS; Hyun MS; Kim MK; Kim H; Park MR; Park J; Kim CS; Kim HJ; Kim YK; Park EK; Zang DY; Jo DY; Lee HW; Yoon YR
Ann Oncol; 2013 Mar; 24(3):756-60. PubMed ID: 23117072
[TBL] [Abstract][Full Text] [Related]
19. Clinical impact of ABCC1 and ABCC2 genotypes and haplotypes in mediating imatinib resistance among chronic myeloid leukaemia patients.
Au A; Baba AA; Azlan H; Norsa'adah B; Ankathil R
J Clin Pharm Ther; 2014 Dec; 39(6):685-90. PubMed ID: 25060527
[TBL] [Abstract][Full Text] [Related]
20. Impact of ABCB1 Gene Polymorphisms and Smoking on the Susceptibility Risk of Chronic Myeloid Leukemia and Cytogenetic Response.
Mohammadi F; Shafiei M; Assad D; Rostami G; Hamid M; Foroughmand AM
Iran Biomed J; 2021 Jan; 25(1):54-61. PubMed ID: 33129240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]